Dexmedetomidine ameliorates TNBS-induced colitis by inducing immunomodulator effect
JOURNAL OF SURGICAL RESEARCH, vol.183, no.2, pp.733-741, 2013 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 183 Issue: 2
- Publication Date: 2013
- Doi Number: 10.1016/j.jss.2013.03.028
- Journal Name: JOURNAL OF SURGICAL RESEARCH
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.733-741
- Keywords: Inflammatory bowel diseases, Dexmedetomidine, Immune response, Cytokines, INTRAABDOMINAL SEPTIC COMPLICATIONS, INFLAMMATORY-BOWEL-DISEASE, REGULATORY T-CELLS, RISK-FACTORS, INTESTINAL INFLAMMATION, GLATIRAMER ACETATE, CROHNS-DISEASE, INTERLEUKIN-10, RESPONSES, SEPSIS
- Eskisehir Osmangazi University Affiliated: No
Abstract
Background: Since sedatives are often administered to immune-compromised and critically ill patients, our understanding of immunomodulation by sedation will be critical. Dexmedetomidine, a selective alpha(2)-adrenergic receptor agonist, is often used for sedation and analgesia especially in intensive care units. There are conflicting and little data concerning both the effect and the mechanism of dexmedetomidine on immune response. In our study, we aimed to investigate the effect of dexmedetomidine on immune system at two different doses (5 mu g.kg(-1) and 30 mu g.kg(-1)) during inflammatory bowel disease by using an experimental model, which resembles both systemic and local inflammation.